# Single Pass

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/single-pass

- Industry: Medical Devices & Equipment
- Headquarters: Lake Forest, US
- Website: www.singlepass.co
- Latest round: Seed (Jul 8, 2021)
- Investors on record: 2

## About

Based in the US, Single Pass, Inc. operates as a medical device company focused on enhancing biopsy procedures through innovative technology that improves safety and effectiveness.Single Pass, Inc. specializes in developing advanced biopsy cauterization devices. Founded in 2021 and headquartered in Lake Forest, US, the company raised seed funding on July 8, 2021, led by Tech Coast Angels and KYTO Technology & Life Science, targeting healthcare facilities for improved biopsy safety.Single Pass, Inc. specializes in the development and manufacturing of a biopsy cauterization device designed to enhance the safety and effectiveness of biopsy procedures. Their core product, the Single Pass probe, operates at a maximum temperature of 90°C, significantly exceeding the temperature range of 46°C to 55°C that is known to cause irreversible cellular damage and cell death. By utilizing this advanced technology, the device aims to improve control over bleeding during biopsy procedures, providing a critical solution for healthcare professionals performing biopsies. Targeting primarily hospitals and outpatient surgical centers, the company serves a diverse clientele, including oncologists, pathologists, and surgical teams involved in diagnostic and therapeutic biopsies. The products are marketed in various geographical regions, including North America, Europe, and parts of Asia, addressing a global need for enhanced biopsy safety protocols.Single Pass, Inc. generates revenue through direct sales of its flagship biopsy cauterization device to healthcare facilities and professionals. The transaction structure is primarily based on direct sales to hospitals and outpatient clinics, where the devices are purchased upfront for use in medical procedures. The pricing plan for the Single Pass probe is aligned with industry standards for specialized medical devices, with potential for volume discounts for larger institutions or recurring orders. The company may also engage in partnerships with distributors to reach a broader market, facilitating access to their products in various clinical settings. Additionally, Single Pass could explore subscription models for ongoing support services or training for healthcare providers, ensuring optimal utilization of their technology in clinical practice.In July 2021, Single Pass, Inc. raised seed funding to expand operations and accelerate growth. The company plans to enhance its product line with new devices tailored to improve biopsy procedures, aiming for market entry by 2023. Additionally, it seeks to penetrate new geographic markets in Europe and Asia by mid-2024, leveraging recent funding to broaden business reach.

## Funding rounds

- Seed, Jul 8, 2021 — Tech Coast Angels, KYTO Technology & Life Science

## Investors

- Tech Coast Angels — Seed
- KYTO Technology & Life Science (https://capitalatlas.ai/funds/kyto-technology-life-science) — Seed